SCHEMBL5599451

SCHEMBL5599451

COc1ccc(Br)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccncc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.43
EPHB4 P54760 1/20 0.43
TEK Q02763 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.42
KDM4E B2RXH2 5/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 2/20 0.41
TRPA1 O75762 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTGER3 P43115 1/20 0.39
ALDH1A1 P00352 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
FLT1 P17948 2/20 0.37
AHR P35869 1/20 0.37
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
HSD17B13 Q7Z5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5959769 0.90 EPHB4 (0.45) KDREPHB4TEKIRAK4KDM4E
SCHEMBL5959882 0.87 MEN1 (0.42) KDREPHB4TEKIRAK4KDM4E
SCHEMBL5585843 0.86 EPHB4 (0.52) KDREPHB4TEKIRAK4KDM4E
SCHEMBL5585827 0.85 POLB (0.49) KDREPHB4TEKIRAK4KDM4E
SCHEMBL3702950 0.84 KDR (0.42) KDREPHB4TEKIRAK4KDM4E
SCHEMBL5592561 0.83 IRAK4 (0.42) KDREPHB4TEKIRAK4KDM4E
SCHEMBL5592763 0.82 EPHB4 (0.46) KDREPHB4TEKIRAK4KDM4E
SCHEMBL3707612 0.82 KDM4E (0.45) KDREPHB4TEKIRAK4KDM4E
SCHEMBL5592761 0.81 KMT2A (0.49) EPHB4IRAK4KDM4EMEN1KMT2A
SCHEMBL5592785 0.80 EPHB4 (0.46) KDREPHB4TEKIRAK4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL KDR 72/4885EPHB4 3357/4885TEK 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.